This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Prior to 1993, no new anticonvulsant medications had been approved by the Food and Drug administration (FDA) in more than 15 years; since that date, 9 have been approved. Three of the drugs have been specifically tested and approved for the treatment of Lennox–Gastaut syndrome (LGS). However, valproic acid, the most commonly prescribed older drug for LGS, is not specifically approved for LGS.1
Fewer than 5% of patients with childhood epilepsy are classified as having LGS,2 but these patients are greatly over-represented in epilepsy clinics because most do not achieve seizure remission. Thus, they return repeatedly, hoping to find a medication that will help. Children who are treated early in their illness and whose seizures are controlled may avoid long-term developmental consequences. Each of the newer medications has had a major impact on a few patients with LGS. Unfortunately, most patients do not respond …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Topics Discussed
Alert Me
Recommended articles
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
The US Food and Drug Administration, neurologists, and drug development and regulation
Child Neurology: Dravet syndrome